TY - JOUR
T1 - Increase in thalamic binding of [11C]PE2I in patients with schizophrenia
T2 - A positron emission tomography study of dopamine transporter
AU - Arakawa, Ryosuke
AU - Ichimiya, Tetsuya
AU - Ito, Hiroshi
AU - Takano, Akihiro
AU - Okumura, Masaki
AU - Takahashi, Hidehiko
AU - Takano, Harumasa
AU - Yasuno, Fumihiko
AU - Kato, Motoichiro
AU - Okubo, Yoshiro
AU - Suhara, Tetsuya
N1 - Funding Information:
This study was supported by a consignment expense for the Molecular Imaging Program on “Research Base for PET Diagnosis” from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japanese Government. The sponsors of the study had no role in the study design, collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.
PY - 2009/10
Y1 - 2009/10
N2 - Previous in vivo imaging studies reported no difference in dopamine transporter (DAT) bindings in the striatum between control subjects and patients with schizophrenia. However, as the signals of radioligands with moderate affinity were insufficient for allowing the evaluation of small amounts of DAT, DAT binding in extrastriatal regions has not been determined. Positron emission tomography scanning using [11C]PE2I was performed on eight patients with schizophrenia and twelve normal control subjects. Binding potential (BPND) for DAT in the caudate, putamen, thalamus and substantia nigra was calculated, using the cerebellum as reference region. In patients with schizophrenia, clinical symptoms were evaluated by Positive and Negative Syndrome Scale (PANSS). BPND in the thalamus of patients with schizophrenia was significantly higher than in control subjects (P = 0.044). In patients with schizophrenia, there were significantly positive correlations between BPND in the thalamus and total (r = 0.75), positive (r = 0.78) and negative PANSS scores (r = 0.82). Altered DAT in the thalamus might be related to the pathophysiology and clinical symptoms of schizophrenia.
AB - Previous in vivo imaging studies reported no difference in dopamine transporter (DAT) bindings in the striatum between control subjects and patients with schizophrenia. However, as the signals of radioligands with moderate affinity were insufficient for allowing the evaluation of small amounts of DAT, DAT binding in extrastriatal regions has not been determined. Positron emission tomography scanning using [11C]PE2I was performed on eight patients with schizophrenia and twelve normal control subjects. Binding potential (BPND) for DAT in the caudate, putamen, thalamus and substantia nigra was calculated, using the cerebellum as reference region. In patients with schizophrenia, clinical symptoms were evaluated by Positive and Negative Syndrome Scale (PANSS). BPND in the thalamus of patients with schizophrenia was significantly higher than in control subjects (P = 0.044). In patients with schizophrenia, there were significantly positive correlations between BPND in the thalamus and total (r = 0.75), positive (r = 0.78) and negative PANSS scores (r = 0.82). Altered DAT in the thalamus might be related to the pathophysiology and clinical symptoms of schizophrenia.
KW - Dopamine transporter
KW - PANSS
KW - Positron emission tomography
KW - Schizophrenia
KW - Thalamus
KW - [C]PE2I
UR - http://www.scopus.com/inward/record.url?scp=70349779416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349779416&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2009.04.009
DO - 10.1016/j.jpsychires.2009.04.009
M3 - Article
C2 - 19457493
AN - SCOPUS:70349779416
SN - 0022-3956
VL - 43
SP - 1219
EP - 1223
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
IS - 15
ER -
